Physician profile
Thomas V Boran
NPI 1497748685
$1,393.32
in general payments reported to CMS, 2019-2025
20 companies · $35.51 in 2025
The $35.51 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $406 · 2021: $468 · 2022: $255 · 2023: $14.89 · 2025: $35.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $211.13 | 2020-2022 | |
| Optinose US, INC. | $209.34 | 2019-2022 | |
| Abbvie INC. | $157.47 | 2019-2021 | |
| Alk-Abello, INC | $154.59 | 2020-2022 | |
| Stryker Corporation | $93.74 | 2019-2025 | Flowtriever |
| Glaxosmithkline, LLC. | $92.02 | 2021-2022 | |
| Amgen INC. | $85.63 | 2020-2021 | |
| Intersect Ent, INC. | $56.28 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.73 | 2019-2021 | |
| Aerin Medical INC. | $51.42 | 2022 | |
| Genzyme Corporation | $48.17 | 2020-2021 | |
| Ibsa Pharma INC. | $34.70 | 2019-2020 | |
| Acclarent, INC | $32.40 | 2019 | |
| Smith+Nephew, INC. | $24.32 | 2021 | |
| Aytu Biopharma, INC. | $18.80 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.64 | 2020 | |
| Medical Device Business Services, INC. | $14.89 | 2023 | Relieva Spinplus |
| Novartis Pharmaceuticals Corporation | $12.94 | 2019 | |
| Phadia US INC. | $12.78 | 2021 | |
| Tactile Systems Technology INC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Boran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.